Showing results (21-30 of 36) with videos related to
Sort By:
Pageof 4
BMC Cancer|November 18, 2021
A novel PDX modeling strategy and its application in metabolomics study for malignant pleural mesotheliomaZhongjian Chen, Chenxi Yang, Zhenying Guo, et al.American Journal of Clinical Pathology|September 20, 2015
INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial NeoplasmsJason N Rosenbaum, Zhenying Guo, Rebecca M Baus, et al.Cancer Cell International|February 23, 2018
Loss of PIM1 correlates with progression and prognosis of salivary adenoid cystic carcinoma (SACC)Jiajie Xu, Xin Zhu, Qingling Li, et al.Cancer Medicine|May 18, 2019
Identification and validation of circulating exosomes-based liquid biopsy for esophageal cancerAn Zhao, Liwei Guo, Ji Xu, et al.Endocrine Pathology|October 16, 2013
The role of epithelial mesenchymal transition markers in thyroid carcinoma progressionCelina Montemayor-Garcia, Heather Hardin, Zhenying Guo, et al.Endocrine Pathology|March 17, 2015
In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic ImplicationsZhenying Guo, Heather Hardin, Celina Montemayor-Garcia, et al.Frontiers in Oncology|December 27, 2021
Aurora Kinase A as a Diagnostic and Prognostic Marker of Malignant MesotheliomaZhenying Guo, Li Shen, Ningning Li, et al.Journal of Immunological Methods|September 28, 2010
Development and evaluation of monoclonal antibodies against phosphatidylethanolamine binding protein 1 in pancreatic cancer patientsXiaoting Wang, Shuangshuang Wang, Xiaojun Tang, et al.The American Journal of Pathology|June 20, 2014
The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progressionHeather Hardin, Zhenying Guo, Weihua Shan, et al.Biomed Research International|December 13, 2019
Clinicopathological and Prognostic Significance of WW Domain Binding Protein 5 Expression in Papillary Thyroid CarcinomaYangyang Qian, Zongfu Pan, Zhenying Guo, et al.Pageof 4